{"news_desk": "Foreign", "print_page": "1", "section_name": "Health", "subsection_name": null, "byline": {"contributor": "Asmaa Al Zohairy\u00a0contributed reporting.", "original": "By DONALD G. McNEIL Jr", "person": [{"middlename": "G.", "firstname": "Donald", "lastname": "McNEIL", "rank": 1, "role": "reported", "qualifier": "Jr", "organization": ""}]}, "abstract": "Pharmaceutical companies are offering hepatitis drugs at fraction of usual cost in Egypt, which has highest rate of infection in world, as part of initiative to cure infectious disease in poor countries while protecting prices and lucrative market in west; at least 10 percent of Egyptians, or nearly 9 million people, are chronically infected with hepatitis; industry's efforts to maintain terms of deal with Egypt and keep drugs from being resold on black market have raised outcry among some rights advocates.", "type_of_material": "News", "word_count": "2199", "lead_paragraph": "A new approach tested in Egypt could become the blueprint for providing cutting-edge medicines to the poor.", "pub_date": "2015-12-16T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Curing Hepatitis C, in an Experiment the Size of Egypt", "print_headline": "Slashing Drug Price to Fight Hepatitis, in Lab the Size of Egypt"}, "snippet": "A new approach tested in Egypt could become the blueprint for providing cutting-edge medicines to the poor.", "multimedia": [{"height": 126, "url": "images/2015/12/16/science/16hepatitis1/16hepatitis1-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/12/16/science/16hepatitis1/16hepatitis1-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 401, "url": "images/2015/12/16/science/16hepatitis1/16hepatitis1-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "401", "xlarge": "images/2015/12/16/science/16hepatitis1/16hepatitis1-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/12/16/science/16hepatitis1/16hepatitis1-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/12/16/science/16hepatitis1/16hepatitis1-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/12/16/health/hepatitis-c-treatment-egypt.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Hepatitis", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Egypt", "name": "glocations"}, {"rank": "3", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Gilead Sciences Inc", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "Sovaldi (Drug)", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Harvoni (Drug)", "name": "subject"}, {"rank": "7", "is_major": "N", "value": "Generic Brands and Products", "name": "subject"}, {"rank": "8", "is_major": "N", "value": "Africa", "name": "glocations"}, {"rank": "9", "is_major": "N", "value": "Acquired Immune Deficiency Syndrome", "name": "subject"}], "blog": [], "_id": "56707d5338f0d803bb110c06", "source": "The New York Times"}